Optically active diazabicyclooctane derivatives and process for preparing the same
Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for β-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R 1 represents CO 2 R, CO 2 M, or CONH 2 , wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R 2 represents a benzyl group or an allyl group.
1. An optically active (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid compound of the following formula (F):
wherein
R 1 represents CO 2 R, wherein R represents a methyl group, a tert-butyl group, or a 2,5-dioxopyrrolidin-1-yl group, and
R 2 represents a benzyl group or an allyl group.
2. A process for preparing the compound of the following formula (F):
wherein
R 1 represents CO 2 R, wherein R represents a methyl group, a tert-butyl group, or a 2,5-dioxopyrrolidin-1-yl group, and
R 2 represents a benzyl group or an allyl group,
which comprises subjecting a compound represented by the following formula (E) to intramolecular urea formation, and then subjecting the resultant compound represented by the following formula (F1) to at least one step of the following steps (a) to (g):
wherein Bn represents a benzyl group, and tBu represents a tert-butyl group,
wherein Bn represents a benzyl group, and tBu represents a tert-butyl group,
step (a) for cleaving the ester of formula (F1),
step (b) for converting the compound of formula (F1) to a form of a salt of an inorganic cation or an organic cation,
step (c) for treating the compound of formula (F1) with an acid to convert the compound of formula (F1) to a free acid,
step (d) for performing carbamoylation for the carboxylic acid group of formula (F1),
step (e) for converting the carboxylic acid of formula (F1) to an ester,
step (f) for removing the benzyl group of the benzyloxy group at the 6-position of the compound of formula (F1), and
a step (g) for converting the group at the 6-position of the compound of formula (F1) to an allyloxy group.
3. A compound which is selected from the group consisting of
(2S,5R)-tert-butyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate,
(2S,5R)-methyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate, and
(2S,5R)-2,5-dioxopyrrolidin-1-yl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate.
4. A crystal of (2S,5R)-tert-butyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 11.56, 10.96, 6.55, 6.00, 5.79, 5.56, 5.47, 5.25, 4.90, 4.35, 4.23, and 3.86 Å.
5. A crystal of (2S,5R)-methyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 10.39, 5.86, 5.69, 5.34, 4.81, 4.44, 3.98, 3.78, 3.11, 3.03, 2.93, and 2.77 Å.
6. A crystal of (2S,5R)-allyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 14.72, 4.91, 4.46, 4.24, and 3.67 Å.
7. A crystal of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid cyclohexylammonium salt, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 9.95, 8.45, 6.26, 5.87, 5.52, 5.22, 5.10, 4.96, 4.73, 4.54, 4.16, 3.93, and 3.55 Å.
8. A crystal of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 8.19, 7.14, 6.64, 6.29, 5.60, 5.21, 4.91, 4.60, 4.21, 3.69, 3.45, and 3.13 Å.
9. A crystal of (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, which exhibits a powder X-ray diffraction pattern having characteristic peaks appearing at lattice spacings (d) of 13.06, 6.52, 5.14, 4.74, 4.63, 4.34, 3.85, and 3.72 Å.
10. The compound of claim 3 , wherein the compound is (2S,5R)-tert-butyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate.
11. The compound of claim 3 , wherein the compound is (2S,5R)-methyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate.
12. The compound of claim 3 , wherein the compound is (2S,5R)-2,5-dioxopyrrolidin-1-yl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate.